Analyst ratings, especially from prominent firms like Oppenheimer, can significantly influence investor sentiment and stock prices. The Outperform rating suggests that Oppenheimer analysts believe Catalyst Pharmaceuticals will perform better than the market or its sector, which can lead to increased investor interest and a potential rise in the stock price. The $30 price target represents a positive outlook on the company's future performance, further bolstering investor confidence.